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Introduction
Uveal melanoma is the most common intraocular malig-
nancy in adults with a disease specific mortality rate of
~40%. Oncogenic mutations in GNAQ and GNA11 were
recently identified as driver mutations in ~90% of uveal
melanoma. While localized disease can be effectively trea-
ted by surgery or radiotherapy, treatment options for
metastatic uveal melanoma are limited. To investigate the
interplay between uveal melanoma and the hosts´ immune
system and to test immunotherapeutic approaches, we
have established an syngenic mouse model of GNAQ
oncogene-driven melanoma.
Materials and methods
Melan-a cells were transduced with retroviruses expressing
an activating Q209L mutation of GNAQ. Tumor formation
was measured with calipers after subcutaneous inoculation
of the cell line in C57BL/6 or RAG2-/- mice. Splenocytes
were harvested at the time of sacrifice. For NK cells deple-
tion, an anti-NK1.1 antibody was administered weekly.
Murine anti-CTLA-4 antibodies (100µg), anti-PD-1 antibo-
dies (250µg) or the combination of both were given weekly
in a therapeutic setting. Peripheral blood mononuclear
cells (PBMC) from uveal melanoma patients were obtained
after informed consent and analyzed by flow cytometry.
Results
Melan-a cells with mutant but not with wt GNAQ form
tumors when injected into mice, resulting in a model of
G-protein-driven experimental murine melanoma (GEM).
No significant difference in tumor growth was observed
between C57BL/6 or RAG2-/- mouse strains. Elimination of
NK cells in RAG2-/- mice led to increased tumor growth
compared to non-depleted controls (p<0.05). Multi-color
flow cytometry revealed a significant increase of CD11b+
Gr-1int myeloid-derived suppressor cells (MDSC) as well as
regulatory T cells (Treg) in tumor-bearing animals as com-
pared to non-tumor-bearing animals. In PBMC from
patients with metastatic uveal melanoma, an increased fre-
quency of monocytic MDSC and Treg was found as com-
pared to healthy controls. In the GEM model, concurrent
administration of an anti-CTLA-4 antibody and an anti-PD-
1-antibody does delay tumor growth significantly (p<0.05)
while monotherapy with either agent did not. No reduction
in the accumulation of Treg and MDSC was found when
comparing treated and untreated mice.
Conclusion
In the syngenic GEM model, tumor growth seems to be
controlled by NK cells and can be delayed by dual
immune checkpoint blockage. In this model, tumor forma-
tion is accompanied by an immunosuppressive leukocyte
network also found in patients with metastatic uveal mela-
noma. Specific elimination of these cells might therefore
synergize with immune checkpoint blocking antibodies.
This hypothesis needs to be tested in future studies to bet-
ter define its treatment potential for patients with
advanced uveal melanoma.
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